Telomir Pharmaceuticals announced that Telomir and Danielle Baker, Ph.D., of Frontage Laboratories will present a scientific poster presentation at the Global Longevity Federation Conference in Las Vegas on March 26th at 2 pm EDT. The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines. The basic theory behind Telomir’s research is the concept that elongating telomeres, which are repetitive DNA sequences at the end of chromosomes that protect chromosomes from becoming frayed or tangled, could result in stimulating stem cell renewal and thus the treatment of age-related conditions like osteoarthritis. “Presenting our poster at the Global Longevity Federation conference offers a significant opportunity for our team to showcase the potential for Telomir-1. Our poster will include new data that demonstrates the results we have had with our lead development product which supports that Telomir-1 may potentially treat age-related conditions and prolong human life,” stated Chris Chapman, MD, Co-founder, Chairman, Chief Executive Officer and President of Telomir Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELO:
- Telomir Pharmaceuticals uses AI testing models to show Telomir-1 potential
- Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science
- Telomir Pharmaceuticals presents preclinical data for Telomir-1
- Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
- Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal